Literature DB >> 22966038

Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.

Karen T Liby1, Michael B Sporn.   

Abstract

We review the rationale for the use of synthetic oleanane triterpenoids (SOs) for prevention and treatment of disease, as well as extensive biological data on this topic resulting from both cell culture and in vivo studies. Emphasis is placed on understanding mechanisms of action. SOs are noncytotoxic drugs with an excellent safety profile. Several hundred SOs have now been synthesized and in vitro have been shown to: 1) suppress inflammation and oxidative stress and therefore be cytoprotective, especially at low nanomolar doses, 2) induce differentiation, and 3) block cell proliferation and induce apoptosis at higher micromolar doses. Animal data on the use of SOs in neurodegenerative diseases and in diseases of the eye, lung, cardiovascular system, liver, gastrointestinal tract, and kidney, as well as in cancer and in metabolic and inflammatory/autoimmune disorders, are reviewed. The importance of the cytoprotective Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1/nuclear factor (erythroid-derived 2)-like 2/antioxidant response element (Keap1/Nrf2/ARE) pathway as a mechanism of action is explained, but interactions with peroxisome proliferator-activated receptor γ (PARPγ), inhibitor of nuclear factor-κB kinase complex (IKK), janus tyrosine kinase/signal transducer and activator of transcription (JAK/STAT), human epidermal growth factor receptor 2 (HER2)/ErbB2/neu, phosphatase and tensin homolog (PTEN), the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, mammalian target of rapamycin (mTOR), and the thiol proteome are also described. In these interactions, Michael addition of SOs to reactive cysteine residues in specific molecular targets triggers biological activity. Ultimately, SOs are multifunctional drugs that regulate the activity of entire networks. Recent progress in the earliest clinical trials with 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) methyl ester (bardoxolone methyl) is also summarized.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22966038      PMCID: PMC3462991          DOI: 10.1124/pr.111.004846

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  293 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  Synthetic triterpenoids target the Arp2/3 complex and inhibit branched actin polymerization.

Authors:  Ciric To; Brian H Shilton; Gianni M Di Guglielmo
Journal:  J Biol Chem       Date:  2010-06-21       Impact factor: 5.157

3.  Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice.

Authors:  Tirumalai Rangasamy; Chung Y Cho; Rajesh K Thimmulappa; Lijie Zhen; Sorachai S Srisuma; Thomas W Kensler; Masayuki Yamamoto; Irina Petrache; Rubin M Tuder; Shyam Biswal
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 4.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

Review 5.  The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration.

Authors:  Jeffrey A Johnson; Delinda A Johnson; Andrew D Kraft; Marcus J Calkins; Rebekah J Jakel; Marcelo R Vargas; Pei-Chun Chen
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

6.  Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.

Authors:  Rajesh K Thimmulappa; Ralph J Fuchs; Deepti Malhotra; Catherine Scollick; Kassim Traore; Jay H Bream; Michael A Trush; Karen T Liby; Michael B Sporn; Thomas W Kensler; Shyam Biswal
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

7.  Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.

Authors:  Melinda S Yates; Mi-Kyoung Kwak; Patricia A Egner; John D Groopman; Sridevi Bodreddigari; Thomas R Sutter; Karen J Baumgartner; B D Roebuck; Karen T Liby; Mark M Yore; Tadashi Honda; Gordon W Gribble; Michael B Sporn; Thomas W Kensler
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

8.  The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

Authors:  Karen Liby; Darlene B Royce; Charlotte R Williams; Renee Risingsong; Mark M Yore; Tadashi Honda; Gordon W Gribble; Ethan Dmitrovsky; Thomas A Sporn; Michael B Sporn
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

9.  Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1.

Authors:  Deepti Malhotra; Rajesh Thimmulappa; Ana Navas-Acien; Andrew Sandford; Mark Elliott; Anju Singh; Linan Chen; Xiaoxi Zhuang; James Hogg; Peter Pare; Rubin M Tuder; Shyam Biswal
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

10.  Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis.

Authors:  Tej K Pareek; Abdelmadjid Belkadi; Sashi Kesavapany; Anita Zaremba; Sook L Loh; Lianhua Bai; Mark L Cohen; Colin Meyer; Karen T Liby; Robert H Miller; Michael B Sporn; John J Letterio
Journal:  Sci Rep       Date:  2011-12-19       Impact factor: 4.379

View more
  135 in total

1.  Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits.

Authors:  Yasuhiro Nakagami; Kayoko Masuda; Emiko Hatano; Tatsuya Inoue; Takuya Matsuyama; Mayumi Iizuka; Yasunori Ono; Takashi Ohnuki; Yoko Murakami; Masaru Iwasaki; Kazuhiro Yoshida; Yuji Kasuya; Satoshi Komoriya
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives.

Authors:  Nisha R Parikh; Animesh Mandal; Deepak Bhatia; Kodappully Sivaraman Siveen; Gautam Sethi; Anupam Bishayee
Journal:  Phytochem Rev       Date:  2014-12       Impact factor: 5.374

3.  Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer.

Authors:  Karen T Liby
Journal:  Dose Response       Date:  2013-08-01       Impact factor: 2.658

4.  Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

Authors:  Ciric To; Carol S Ringelberg; Darlene B Royce; Charlotte R Williams; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Carcinogenesis       Date:  2015-05-04       Impact factor: 4.944

5.  Computational and Synthetic Investigation of Cationic Rearrangement in the Putative Biosynthesis of Justicane Triterpenoids.

Authors:  Masha Elkin; Anthony C Scruse; Aneta Turlik; Timothy R Newhouse
Journal:  Angew Chem Int Ed Engl       Date:  2018-12-21       Impact factor: 15.336

6.  A generalizable platform for interrogating target- and signal-specific consequences of electrophilic modifications in redox-dependent cell signaling.

Authors:  Hong-Yu Lin; Joseph A Haegele; Michael T Disare; Qishan Lin; Yimon Aye
Journal:  J Am Chem Soc       Date:  2015-05-05       Impact factor: 15.419

7.  The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

Authors:  Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-09

8.  Bardoxolone brings Nrf2-based therapies to light.

Authors:  Donna D Zhang
Journal:  Antioxid Redox Signal       Date:  2013-01-11       Impact factor: 8.401

Review 9.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

Review 10.  Beyond oxidative stress: an immunologist's guide to reactive oxygen species.

Authors:  Carl Nathan; Amy Cunningham-Bussel
Journal:  Nat Rev Immunol       Date:  2013-05       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.